article thumbnail

Synlogic gets grant for genetically engineered bacteria for attenuating metabolic diseases

Pharmaceutical Technology

Discover how Synlogic Inc's patented genetically engineered bacteria produce short-chain fatty acids to combat metabolic diseases. Learn more about this innovative treatment approach.

article thumbnail

Yield10 Bioscience gets grant for genetically engineered oilseed plant expressing plant protein

Pharmaceutical Technology

Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DrugPatentWatch named “Best of the Web” by Genetic Engineering News

Drug Patent Watch

DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile highlighted the “new training modules designed to help you find….

article thumbnail

The Importance of Hazard Communications in Clinical Trials Involving Genetic Engineering

Advarra

Genetically engineered products often require additional safety practices to ensure the infectious agents do not endanger participants, study staff, or the broader environment where such agents are administered. How can I protect myself from exposure? What should I do if I’m exposed?

article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

article thumbnail

Synlogic gets grant for genetically engineered bacteria for treating phenylketonuria

Pharmaceutical Technology

Discover how Synlogic Inc's patented genetically programmed microorganisms can modulate and treat diseases. Learn about the innovative method for producing pharmaceutical compositions using non-pathogenic bacteria to metabolize phenylalanine. Explore the potential applications in gut microbiome and tumor environments.